Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19
NCT ID: NCT04910230
Last Updated: 2021-11-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2020-03-01
2020-04-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
nicotinamide plus usual care
nicotinamide
In addition to usual care, the treatment group was given 500mg nicotinamide daily, divided into 5 doses
usual care
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
nicotinamide
In addition to usual care, the treatment group was given 500mg nicotinamide daily, divided into 5 doses
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* aged 18-85
* the absolute lymphocyte counts below the normal value (\<1.1-3.2×109/L)
Exclusion Criteria
* women who are pregnant or lactating
* ALT/AST \> 5 times upper limit of normal (ULN), neutrophils counts \< 0.5×109/L, platelets counts\< 50×109/L
* patients diagnosed with rheumatoid immune-related diseases
* patients who take long-term oral anti-rejection drugs or immunomodulatory drugs
* hypersensitive reaction to nicotinamide or any auxiliary materials
* patients with active tuberculosis or combined with bacterial and fungal infections
* patients undergoing organ transplant
* patients with mental disorders.
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Qiang Hu
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Qiang Hu
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Quan-Yu L Zhang, phD
Role: PRINCIPAL_INVESTIGATOR
Department of Cardiology, General Hospital of Northern Theater Command, Shenyang 110016, China
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
General Hospital of Northern Theater Command
Shenyang, Liaoning, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hu Q, Zhang QY, Peng CF, Ma Z, Han YL. Efficiency of nicotinamide-based supportive therapy in lymphopenia for patients with ordinary or severe COVID-19: A randomized controlled trial. Medicine (Baltimore). 2022 Oct 28;101(43):e31138. doi: 10.1097/MD.0000000000031138.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N2020-12
Identifier Type: -
Identifier Source: org_study_id